Entrectinib purchase and analysis of its effects

Introduction: Entrectinib is a targeted therapy drug used to treat patients with solid tumors carrying NTRK gene fusions and patients with ROS1-positive non-small cell lung cancer (NSCLC). Generic drugs of Entrectinib are currently on the market. This article mainly talks about the purchase method, effects and medication of entrectinib for special groups.

Purchase method

1. Hospital pharmacy: Patients can purchase entrectinib in the hospital pharmacy with a doctor's prescription.

2. Online pharmacies: Some regular online pharmacies may sell entrectinib, and patients can purchase it through online pharmacies after obtaining a doctor's prescription.

3. Regular overseas medical service machines: Patients can also choose to obtain entrectinib, including the generic version, through the help of regular overseas medical service machines. They may have cooperation with pharmacies at home and abroad, which can help patients obtain the medicine and ensure that it is genuine.

Enrectinib is a prescription drug and must be sold, dispensed and used with a physician's prescription. Before purchasing, patients first need to consult and be evaluated by a lung cancer specialist to ensure entrectinib is a suitable treatment option.

Effects

1. High response rate: Entrectinib shows a high proportion of durable objective response (ORR) in patients with NTRK fusion-positive advanced solid tumors, and also shows high intracranial activity in patients with CNS (central nervous system) metastasis at baseline.

2. Intracranial efficacy: Entrectinib can penetrate the blood-brain barrier and is effective in primary and metastatic brain diseases, which gives it significant advantages in the treatment of patients with brain metastases.

3. Long-term survival: The median progression-free survival (PFS) of patients treated with entrectinib can reach 17.7 months, and the median overall survival (OS) is 47.7 months, showing deep and durable systemic effects.

Medication for Special Populations

Entrectinib is suitable for children aged 12 years and above. In elderly patients (patients aged ≥ 65 years), entrectinib may be considered, but the dose should be adjusted on an individual basis. There is currently no clear medication guidance for patients with severe renal insufficiency. Patients with hepatic impairment should use with caution. Female patients of childbearing potential should have a supervised pregnancy test before starting treatment with . The safety profile of entrectinib is good, with no black box warning, and most adverse reactions are grade 1/2 and can be managed.

As a new type of targeted drug, entrectinib provides a new treatment option for tumor patients carrying specific gene mutations, especially for those patients whose traditional treatment methods are ineffective. Entrectinib should be used under the guidance of a physician and requires regular monitoring of patient response and potential adverse reactions.